Designer drugs: mechanism of action and adverse effects
Open accessThe DOI matches its Crossref record; 658 of the 659 references it cites were found in a registry or an index.
Abstract
Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precipitous increase in novel and designer drugs (eg, cathinones, amphetamines) in the market complicates the clinical picture.3”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987) · Science · doi:10.1126/science.2820058 · Cited by 2,180
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,731
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,213
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · cited 5×
“Similar to other psychedelics, tryptamine psychedelics alter perception and can induce psychological disturbances in users, including acute psychosis (Meatherall and Sharma 2003; Nichols 2004, 2016; Shulgin and Shulgin 1997; Taljemark and Johansson 2012).”
InfluentialMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Endocannabinoid Signaling and Synaptic Function
Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.020 · Cited by 1,120
Gart, E., Souto Lima, E., Schuren, F., De Ruiter, C. G. F., Attema, J., Verschuren, L., Keijer, J., Salic, K., Morrison, M. C., & Kleemann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010001 · Cited by 1,093
Molecular mechanisms of opioid receptor-dependent signaling and behavior
Al-Hasani, R., & Bruchas, M. R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238bba6 · Cited by 1,067
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
The dopamine hypothesis of the reinforcing properties of cocaine
Kuhar, M. J., Ritz, M. C., & Boja, J. W. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90141-g · Cited by 987
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2000) · Synapse · doi:10.1002/1098-2396(20010101)39:1<16::aid-syn3>3.0.co;2-# · Cited by 948
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821 · cited 1×
“5) has critically contributed to the opioid crisis, particularly in the United States (Daniulaityte et al. 2017; Denton et al. 2008; Lucyk and Nelson 2017; Peterson et al. 2016; Rudd et al. 2016; Scholl et al. 2018; Seth et al. 2018).”
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
New Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
Henry, J. A., Jeffreys, K. J., & Dawling, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)91469-o · Cited by 729
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
Armenian, P., Vo, K. T., Barr-Walker, J., & Lynch, K. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.016 · Cited by 710
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Pharmacological characterization of designer cathinones in vitro
Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M., & Liechti, M. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02145.x · Cited by 672
Self-citationShulgin, A. T., & Shulgin, A. (1991) · Cited by 668
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
Pharmacology of anabolic steroids
Kicman, A. T. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.165 · Cited by 580
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Monoamine transporters and psychostimulant drugs
Rothman, R. B., & Baumann, M. H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.054 · Cited by 502
Opioids: first lessons from knockout mice
Kieffer, B. L. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01279-6 · Cited by 489
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 1×
“The activation of 5-HT2B receptors in cardiovascular tissues may potentially result in cardiac valvulopathy and is thus a concern for drugs that increase plasma 5-HT levels or directly activate 5-HT2B receptors (Elangbam 2010; Elangbam et al. 2008; Huang et al. 2009; Roth 2007).”
BackgroundSternbach, L. H. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00187a001 · Cited by 448
A review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Baumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., Brandt, S. D., Rothman, R. B., Ruoho, A. E., & Cozzi, N. V. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.304 · Cited by 439
Toxicity of amphetamines: an update
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 431
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
Self-citationPreller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
Self-citationWang, H., Wang, J., Bai, Y., Li, J., Li, L., & Dong, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010001 · Cited by 390
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390
Codd, E. E., Shank, R. P., Schupsky, J. J., & Raffa, R. B. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10630-7 · Cited by 388
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Self-citationTait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016) · Clinical Toxicology · doi:10.3109/15563650.2015.1110590 · Cited by 378
Stanley, T. H. (2014) · The Journal of Pain · doi:10.1016/j.jpain.2014.08.010 · Cited by 352
Khat and synthetic cathinones: a review
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F., & Carvalho, M. (2014) · Archives of Toxicology · doi:10.1007/s00204-013-1163-9 · Cited by 337
Winstock, A. R., & Barratt, M. J. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.011 · Cited by 331
Synthetic Cannabinoid–Related Illnesses and Deaths
Trecki, J., Gerona, R. R., & Schwartz, M. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1505328 · Cited by 331
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Acute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 302
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Clinical toxicology of newer recreational drugs
Hill, S. L., & Thomas, S. H. L. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.615318 · Cited by 290
Gladden, R. M., O’Donnell, J., Mattson, C. L., & Seth, P. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6834a2 · Cited by 284
Misuse of Novel Synthetic Opioids: A Deadly New Trend
Prekupec, M. P., Mansky, P. A., & Baumann, M. H. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000324 · Cited by 283
Withdrawal Phenomena and Dependence Syndrome After the Consumption of „Spice Gold“
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0464 · Cited by 278
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
Amphetamines, new psychoactive drugs and the monoamine transporter cycle
Sitte, H. H., & Freissmuth, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.006 · Cited by 276
Myocardial Infarction Associated With Use of the Synthetic Cannabinoid K2
Mir, A., Obafemi, A., Young, A., & Kane, C. (2011) · Pediatrics · doi:10.1542/peds.2010-3823 · Cited by 266
Atwood, B. K., Huffman, J., Straiker, A., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00582.x · Cited by 262
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Baumann, M. H., Clark, R. D., Budzynski, A. G., Partilla, J. S., Blough, B. E., & Rothman, R. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300585 · Cited by 248
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247
Self-citationBanister, S. D., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J. B. C., Glass, M., McGregor, I. S., Connor, M., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00137 · Cited by 245
From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs
Morris, H., & Wallach, J. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1620 · Cited by 244
The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
van Amsterdam, J., Brunt, T., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565142 · Cited by 244
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · cited 1×
“…tachycardia, chest pain, palpitations, anorexia, nausea, vomiting, and abdominal pain) can be expected for newly emerged amphetamine-derived designer drugs (Carvalho et al. 2012; Derlet et al. 1989; Dolder et al. 2017; Heal et al. 2013; Vizeli and Liechti 2017; Wijers et al. 2017).”
BackgroundSelf-citationBanister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Glass, M., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00112 · Cited by 234
Synthetic Cannabinoid Intoxication: A Case Series and Review
Harris, C. R., & Brown, A. (2013) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.07.061 · Cited by 232
Substituted methcathinones differ in transporter and receptor interactions
Eshleman, A. J., Wolfrum, K. M., Hatfield, M. G., Johnson, R. A., Murphy, K. V., & Janowsky, A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.004 · Cited by 229
Borek, H. A., & Holstege, C. P. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.01.005 · Cited by 223
Shulgin, A. T., & Shulgin, A. (1997) · Cited by 223
Busardo, F., & Jones, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215423 · Cited by 217
Rickli, A., Luethi, D., Reinisch, J., Buchy, D., Hoener, M. C., & Liechti, M. E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.034 · Cited by 215
Self-citationBraden, M. R., Parrish, J. C., Naylor, J. C., & Nichols, D. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028720 · Cited by 215
Case series of individuals with analytically confirmed acute mephedrone toxicity
Wood, D. M., Davies, S., Greene, S. L., Button, J., Holt, D. W., Ramsey, J., & Dargan, P. I. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.531021 · Cited by 215
James, D., Adams, R. D., Spears, R., Cooper, G., Lupton, D. J., Thompson, J. P., Thomas, S. H. L., & Service, O. B. O. T. N. P. I. (2011) · Emergency Medicine Journal · doi:10.1136/emj.2010.096636 · Cited by 214
Fleckenstein, A. E., Gibb, J. W., & Hanson, G. R. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00639-7 · Cited by 213
Marinetti, L. J., & Antonides, H. M. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bks136 · Cited by 213
Phenibut (β‐Phenyl‐GABA): A Tranquilizer and Nootropic Drug
Lapin, I. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00211.x · Cited by 212
A 3-year review of new psychoactive substances in casework
Elliott, S., & Evans, J. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.04.017 · Cited by 212
Severe Toxicity Following Synthetic Cannabinoid Ingestion
Lapoint, J., James, L. P., Moran, C. L., Nelson, L. S., Hoffman, R. S., & Moran, J. H. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.609822 · Cited by 212
Wee, S., Anderson, K. G., Baumann, M. H., Rothman, R. B., Blough, B. E., & Woolverton, W. L. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080101 · Cited by 211
Psychoactive “bath salts”: Not so soothing
Baumann, M. H., Partilla, J. S., & Lehner, K. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.020 · Cited by 208
The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol
Schep, L. J., Knudsen, K., Slaughter, R. J., Vale, J. A., & Mégarbane, B. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.702218 · Cited by 206
2C or Not 2C: Phenethylamine Designer Drug Review
Dean, B. V., Stellpflug, S. J., Burnett, A. M., & Engebretsen, K. M. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0295-x · Cited by 204
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
Simmler, L. D., Rickli, A., Hoener, M. C., & Liechti, M. E. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.008 · Cited by 200
Self-citationThe origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*
Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01511.x · Cited by 199
Mohr, A. L. A., Friscia, M., Papsun, D., Kacinko, S. L., Buzby, D., & Logan, B. K. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw086 · Cited by 199
Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Hibbs, D. E., Glass, M., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00107 · Cited by 197
Rickli, A., Hoener, M. C., & Liechti, M. E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.012 · Cited by 195
Self-citationPapanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., Impagnatiello, M., Pascolo‐Fabrici, E., & Bonavigo, T. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2312 · Cited by 190
Increases in Fentanyl-Related Overdose Deaths — Florida and Ohio, 2013–2015
Peterson, A. B., Gladden, R. M., Delcher, C., Spies, E., Garcia-Williams, A., Wang, Y., Halpin, J., Zibbell, J., McCarty, C. L., DeFiore-Hyrmer, J., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6533a3 · Cited by 188
Hoyte, C. O., Jacob, J., Monte, A. A., Al-Jumaan, M., Bronstein, A. C., & Heard, K. J. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.03.007 · Cited by 186
Müller, H., Sperling, W., Köhrmann, M., Huttner, H. B., Kornhuber, J., & Maler, J.-M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.001 · Cited by 183
Ecstasy: A common cause of severe acute hepatotoxicity
Andreu, V., Mas, A., Bruguera, M., Salmerón, J. M., Moreno, V., Nogué, S., & Rodés, J. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80056-1 · Cited by 182
Mephedrone (4-Methylmethcathinone)-Related Deaths
Maskell, P. D., De Paoli, G., Seneviratne, C., & Pounder, D. J. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.3.188 · Cited by 179
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Kraehenmann, R., Pokorny, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E., & Vollenweider, F. X. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4610-0 · Cited by 176
Neurochemical profiles of some novel psychoactive substances
Iversen, L., Gibbons, S., Treble, R., Setola, V., Huang, X.-P., & Roth, B. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.006 · Cited by 175
Psychosis Associated With Synthetic Cannabinoid Agonists: A Case Series
Hurst, D., Loeffler, G. H., & McLay, R. N. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010176 · Cited by 173
Three Fatal Intoxications Due to Methylone
Pearson, J. M., Hargraves, T. L., Hair, L. S., Massucci, C. J., Clinton Frazee, C., Garg, U., & Pietak, B. R. (2012) · Journal of Analytical Toxicology · doi:10.1093/jat/bks043 · Cited by 171
Uncoupling the agony from ecstasy
Mills, E., Banks, M. L., Sprague, J. E., & Finkel, T. (2003) · Nature · doi:10.1038/426403a · Cited by 170
Focus on cannabinoids and synthetic cannabinoids
Le Boisselier, R., Alexandre, J., Lelong‐Boulouard, V, & Debruyne, D. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.563 · Cited by 169
Methylenedioxypyrovalerone (“Bath Salts”),Related Death: Case Report and Review of the Literature,
Kesha, K., Boggs, C. L., Ripple, M. G., Allan, C. H., Levine, B., Jufer‐Phipps, R., Doyon, S., Chi, P., & Fowler, D. R. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12202 · Cited by 167
Piperazine compounds as drugs of abuse
Arbo, M. D., Bastos, M. L., & Carmo, H. F. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.007 · Cited by 167
Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22
Behonick, G., Shanks, K. G., Firchau, D. J., Mathur, G., Lynch, C. F., Nashelsky, M., Jaskierny, D. J., & Meroueh, C. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku048 · Cited by 165
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., & Ruoho, A. E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0308-8 · Cited by 162
Bäckberg, M., Beck, O., Jönsson, K., & Helander, A. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1054505 · Cited by 161
Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter
Partilla, J. S., Dempsey, A. G., Nagpal, A., Blough, B. E., Baumann, M. H., & Rothman, R. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103622 · Cited by 161
MT-45, a new psychoactive substance associated with hearing loss and unconsciousness
Helander, A., Bäckberg, M., & Beck, O. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.943908 · Cited by 161
Ketamine‐associated bladder dysfunction
Tsai, T., Cha, T., Lin, C., Tsao, C., Tang, S., Chuang, F., Wu, S., Sun, G., Yu, D., & Chang, S. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02361.x · Cited by 161
Acute liver damage and ecstasy ingestion.
Ellis, A. J., Wendon, J. A., Portmann, B., & Williams, R. (1996) · Gut · doi:10.1136/gut.38.3.454 · Cited by 160
Postmortem Tissue Distribution of MDPV Following Lethal Intoxication by "Bath Salts"
Wyman, J. F., Lavins, E. S., Engelhart, D., Armstrong, E. J., Snell, K. D., Boggs, P. D., Taylor, S. M., Norris, R. N., & Miller, F. P. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bkt001 · Cited by 160
Hill, S. L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M., Blain, P., & Thomas, S. H. L. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.802795 · Cited by 158
Helander, A., Bäckberg, M., & Beck, O. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1139715 · Cited by 158
Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse
Screaton, G. R., Cairns, H., Sarner, M., Singer, M., Thrasher, A. J., & Cohen, S. L. (1992) · The Lancet · doi:10.1016/0140-6736(92)90834-p · Cited by 157
Rhabdomyolysis and Shock After Intravenous Amphetamine Administration
KENDRICK, W. C., HULL, A. R., & KNOCHEL, J. P. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-4-381 · Cited by 154
Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., & Iversen, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059334 · Cited by 154
Amphetamine toxicity: Experience with 127 cases
Derlet, R. W., Rice, P., Horowitz, B. Z., & Lord, R. V. (1989) · Journal of Emergency Medicine · doi:10.1016/0736-4679(89)90263-1 · Cited by 154
Gee, P., Richardson, S. K., Woltersdorf, W. W. W., & Moore, G. (2005) · PubMed · Cited by 152
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 152
The emergence of new psychoactive substance (NPS) benzodiazepines: A review
Manchester, K. R., Lomas, E. C., Waters, L. J., Dempsey, F. C., & Maskell, P. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2211 · Cited by 150
Behavioral analyses of GHB: Receptor mechanisms
Carter, L. P., Koek, W., & France, C. P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.003 · Cited by 149
Synthetic cannabinoid drug use as a cause or contributory cause of death
Labay, L. M., Caruso, J. L., Gilson, T. P., Phipps, R., Knight, L. D., Lemos, N. P., McIntyre, I. M., Stoppacher, R., Tormos, L. M., Wiens, A. L., et al. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2015.12.046 · Cited by 149
Charbogne, P., Kieffer, B. L., & Befort, K. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.028 · Cited by 147
Armenian, P., Olson, A., Anaya, A., Kurtz, A. M., Ruegner, R., & Gerona, R. R. L. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.06.014 · Cited by 147
Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid
Carai, M. A. M., Colombo, G., Brunetti, G., Melis, S., Serra, S., Vacca, G., MASTINU, S., Pistuddi, A. M., Solinas, C., Cignarella, G., et al. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01334-6 · Cited by 146
Safety pharmacology of acute MDMA administration in healthy subjects
Vizeli, P., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691569 · Cited by 145
Self-citationSklerov, J., Levine, B., Moore, K. A., King, T., & Fowler, D. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.838 · Cited by 144
Elliott, S. P., Brandt, S. D., & Smith, C. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1984 · Cited by 144
Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone.
Ross, E., Reisfield, G., Watson, M., Chronister, C. W., & Goldberger, B. (2012) · American Journal of Medicine · doi:10.1016/j.amjmed.2012.02.019 · Cited by 143
An expanding world of new psychoactive substances—designer benzodiazepines
Zawilska, J. B., & Wojcieszak, J. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.02.015 · Cited by 143
Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors
Maguire, P. A., Tsai, N. F., Kamal, J., Cometta–Morini, C., Upton, C., & Loew, G. H. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90685-w · Cited by 141
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 140
AKI Associated with Synthetic Cannabinoids
Bhanushali, G. K., Jain, G., Fatima, H., Leisch, L. J., & Thornley‐Brown, D. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05690612 · Cited by 139
Ischemic stroke after use of the synthetic marijuana “spice”
Freeman, M. J., Rose, D. Z., Myers, M. A., Gooch, C. L., Bozeman, A. C., & Burgin, W. S. (2013) · Neurology · doi:10.1212/01.wnl.0000437297.05570.a2 · Cited by 138
Papsun, D., Krywanczyk, A., Vose, J. C., Bundock, E. A., & Logan, B. K. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw012 · Cited by 137
Banister, S. D., & Connor, M. A. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_144 · Cited by 137
An Acute Acetyl Fentanyl Fatality: A Case Report With Postmortem Concentrations
McIntyre, I. M., Trochta, A., Gary, R. D., Malamatos, M., & Lucas, J. R. (2015) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv043 · Cited by 136
'Street ketamine'-associated bladder dysfunction: a report of ten cases.
Chu, P. S. K., Kwok, S. C., Lam, K. M., Chu, T., Chan, S. W. H., Man, C. W., Ma, W. K., Chui, K. L., Yiu, M. K., Chan, Y. C., et al. (2007) · PubMed · Cited by 134
Schep, L. J., Slaughter, R. J., Vale, J. A., Beasley, D. M. G., & Gee, P. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.572076 · Cited by 134
Eshleman, A. J., Wolfrum, K. M., Reed, J. F., Kim, S. O., Swanson, T. L., Johnson, R. A., & Janowsky, A. J. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236349 · Cited by 134
Drug-induced Valvulopathy: An Update
Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 133
Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation
Young, A. C., Schwarz, E. S., Medina, G., Obafemi, A. I., Feng, S., Kane, C., & Kleinschmidt, K. (2011) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2011.05.013 · Cited by 132
Colado, M. I., Murray, T. K., & Green, A. R. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb12846.x · Cited by 132
Postmortem and Toxicological Findings in a Series of Furanylfentanyl-Related Deaths
Guerrieri, D., Rapp, E., Roman, M., Druid, H., & Kronstrand, R. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw129 · Cited by 132
Acute kidney injury associated with smoking synthetic cannabinoid
Buser, G. L., Gerona, R. R. L., Horowitz, B. Z., Vian, K., Troxell, M. L., Hendrickson, R. G., Houghton, D. C., Rozansky, D. J., Su, S. W., & Leman, R. F. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.932365 · Cited by 130
Methamphetamine abuse and rhabdomyolysis in the ED: A 5-year study
Richards, J. R., Johnson, E. B., Stark, R. W., & Derlet, R. W. (1999) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(99)90159-6 · Cited by 130
Synthetic cannabinoid and marijuana exposures reported to poison centers
Forrester, M., Kleinschmidt, K., Schwarz, E. S., & Young, A. (2012) · Human & Experimental Toxicology · doi:10.1177/0960327111421945 · Cited by 129
Campbell, G. A., & Rosner, M. H. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02080508 · Cited by 129
Pharmacological profile of novel psychoactive benzofurans
Rickli, A., Kopf, S., Hoener, M. C., & Liechti, M. E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13128 · Cited by 128
Self-citationPostmortem Toxicology of New Synthetic Opioids
Concheiro, M., Chesser, R., Pardi, J., & Cooper, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01210 · Cited by 128
A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy
Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H., & Honda, K. (2006) · Forensic Science International · doi:10.1016/j.forsciint.2005.11.026 · Cited by 127
Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
Burns, G., DeRienz, R. T., Baker, D. D., Casavant, M., & Spiller, H. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157722 · Cited by 126
Cathinone: An Investigation of Several N-Alkyl and Methylenedioxy-Substituted Analogs
Cason, T. A. D., Young, R., & Glennon, R. A. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00323-7 · Cited by 125
Two Fatal Intoxications Involving Butyryl Fentanyl
Poklis, J., Poklis, A., Wolf, C., Hathaway, C., Arbefeville, E., Chrostowski, L., Devers, K., Hair, L., Mainland, M., Merves, M., et al. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw048 · Cited by 124
Driving under the influence of synthetic cannabinoids (“Spice”): a case series
Mußhoff, F., Madea, B., Kernbach-Wighton, G., Bicker, W., Kneisel, S., Hutter, M., & Auwärter, V. (2013) · International Journal of Legal Medicine · doi:10.1007/s00414-013-0864-1 · Cited by 123
Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA
Shanks, K. G., Clark, W., & Behonick, G. S. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv142 · Cited by 123
Amphetamine Intoxication with Coagulopathy, Hyperthermia, and Reversible Renal Failure
Ginsberg, M. D., HERTZMAN, M., & SCHMIDT-NOWARA, W. W. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-1-81 · Cited by 122
Fatal Intoxication with Acetyl Fentanyl
Cunningham, S. M., Haikal, N. A., & Kraner, J. C. (2015) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12953 · Cited by 120
Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives
Simmler, L. D., Rickli, A., Schramm, Y., Hoener, M. C., & Liechti, M. E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.024 · Cited by 120
Self-citationBupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent
Soroko, F. E., Mehta, N. B., Maxwell, R. A., Ferris, R. M., & Schroeder, D. H. (1977) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1977.tb11460.x · Cited by 119
Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion
Hartung, T. K. (2002) · QJM · doi:10.1093/qjmed/95.7.431 · Cited by 119
Convulsions Associated with the Use of a Synthetic Cannabinoid Product
Schneir, A., & Baumbacher, T. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0182-2 · Cited by 119
Case series of 226 γ-hydroxybutyrate–associated deaths: lethal toxicity and trauma
Zvosec, D. L., Smith, S. W., Porrata, T., Strobl, A. Q., & Dyer, J. E. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.11.008 · Cited by 119
Pharmacological profile of mephedrone analogs and related new psychoactive substances
Luethi, D., Kolaczynska, K. E., Docci, L., Krähenbühl, S., Hoener, M. C., & Liechti, M. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.026 · Cited by 119
Self-citationUnravelling the brain targets of γ-hydroxybutyric acid
CRUNELLI, V, EMRI, Z., & LERESCHE, N. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.001 · Cited by 118
Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine
Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A. E., & Dargan, P. I. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1199-9 · Cited by 117
Ross, E. A., Watson, M., & Goldberger, B. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1107097 · Cited by 117
Baldo, B. A. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2244-6 · Cited by 117
Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review
Kim, H. K., & Nelson, L. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1037274 · Cited by 116
Detection of JWH-018 and JWH-073 by UPLC-MS-MS in Postmortem Whole Blood Casework
Shanks, K. G., Dahn, T., & Terrell, A. R. (2012) · Journal of Analytical Toxicology · doi:10.1093/jat/bks013 · Cited by 116
Law, R., Schier, J. G., Martin, C. A., Chang, A. S., & Wolkin, A. F. (2015) · PubMed Central · Cited by 116
Elangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L., Gates, L. D., & Slocum, N. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.03.005 · Cited by 115
Moya, P. R., Berg, K. A., Gutierrez-Hernandez, M., Sáez‐Briones, P., Reyes-Parada, M. I., Cassels, B. K., & Clarke, W. P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117507 · Cited by 115
Schifano, F., Corkery, J., & Ghodse, A. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318266c70c · Cited by 114
Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA
Westin, A. A., Frost, J., Brede, W. R., Gundersen, P. O. M., Einvik, S., Aarset, H., & Slørdal, L. (2015) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv110 · Cited by 114
Simmler, L. D., Buchy, D., Chaboz, S., Hoener, M. C., & Liechti, M. E. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229765 · Cited by 114
Self-citationNichols, D. E., & Grob, C. S. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.01.006 · Cited by 114
A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug
Rose, S. R., Poklis, J. L., & Poklis, A. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.772191 · Cited by 113
Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease
Droogmans, S., Cosyns, B., D’Haenen, H., Creeten, E., Weytjens, C., Franken, P. R., Scott, B., Schoors, D. F., Kemdem, A., Close, L., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.045 · Cited by 112
Siddiqi, S., Verney, C., Dargan, P., & Wood, D. M. (2015) · Clinical Toxicology · doi:10.3109/15563650.2014.983239 · Cited by 112
Overdose Deaths Related to Fentanyl and Its Analogs — Ohio, January–February 2017
Daniulaityte, R., Juhascik, M. P., Strayer, K. E., Sizemore, I. E., Harshbarger, K. E., Antonides, H. M., & Carlson, R. R. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6634a3 · Cited by 112
Baumann, M. H., Ayestas, M. A., Dersch, C. M., Brockington, A., Rice, K. C., & Rothman, R. B. (2000) · Synapse · doi:10.1002/(sici)1098-2396(200005)36:2<102::aid-syn3>3.0.co;2-# · Cited by 111
Halberstadt, A. L., & Geyer, M. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.025 · Cited by 110
Sudden Cardiac Death Associated With Methylone Use
Carbone, P. N., Carbone, D. L., Carstairs, S. D., & Luzi, S. A. (2013) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0b013e31827ab5da · Cited by 110
Fatalities Involving Carfentanil and Furanyl Fentanyl: Two Case Reports
Swanson, D. M., Hair, L. S., Strauch Rivers, S. R., Smyth, B. C., Brogan, S. C., Ventoso, A. D., Vaccaro, S. L., & Pearson, J. M. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx037 · Cited by 110
An Acute Butyr-Fentanyl Fatality: A Case Report with Postmortem Concentrations
McIntyre, I. M., Trochta, A., Gary, R. D., Wright, J., & Mena, O. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkv138 · Cited by 109
The Synthetic Cannabinoid Withdrawal Syndrome
Nacca, N. E., Vatti, D., Sullivan, R. W., Sud, P., Su, M. K., & Marraffa, J. M. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31828e1881 · Cited by 107
Rhabdomyolysis After Ingestion of “Foxy,” a Hallucinogenic Tryptamine Derivative
Alatrash, G., Majhail, N. S., & Pile, J. C. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.4.550 · Cited by 106
Death after use of the synthetic cannabinoid 5F-AMB
Shanks, K. G., & Behonick, G. S. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.03.004 · Cited by 106
Ott, J. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10399925 · Cited by 105
Synthetic cathinones related fatalities: an update.
Zaami, S., Giorgetti, R., Pichini, S., Pantano, F., Marinelli, E., & Busardò, F. P. (2018) · PubMed · doi:10.26355/eurrev_201801_14129 · Cited by 105
Research works printed but not linked: 5
- Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
- Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
- Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
- Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
- Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Anghel, D.-M. C., Nițescu, G. V., Tiron, A. T., Guțu, C. M., & Baconi, D. L. (2023) · Molecules · doi:10.3390/molecules28134969 · Cited by 124
A review of synthetic cathinones emerging in recent years (2019–2022)
Kuropka, P., Zawadzki, M., & Szpot, P. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00639-5 · Cited by 79
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 68
Metadata
- Authors
- Luethi, D., & Liechti, M. E.
- Affiliations
- TU Wien (AT)
- University of Basel (CH)
- Corresponding author
- Luethi, Dino
- Venue
- Archives of Toxicology
- Published
- 2020-04
- Volume
- 94
- Issue
- 4
- Pages
- 1085-1133
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC7225206
- OpenAlex
- W3014121938
- Cited by
- 262
- References
- 659
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 43 · 2023: 42 · 2022: 55 · 2021: 35 · 2020: 13
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-03-03)
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 5 d)
- Locations
- Archives of Toxicology (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_181809)
- Bundesamt für Gesundheit (16.921318)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- new psychoactive substances, mechanism of action, adverse drug reactions, stimulants, cathinone, monoamine transporters, sympathomimetic effects, sedatives, mu-opioid receptor agonism, GABA receptors, cardiorespiratory depression, dissociative drugs, NMDA receptor antagonists, ketamine, synthetic cannabinoids, CB1 receptor, serotonergic psychedelics, 5-HT2A receptor, drug screening, polydrug use
- MeSH terms
- Central Nervous System Stimulants, Cannabinoids, Hallucinogens, Humans, Psychotropic Drugs, Serotonin, Illicit Drugs, Designer Drugs, Molecular Structure, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.